Entering text into the input field will update the search result below

Pluristem joins AI-based genome-editing consortium

  • Pluristem Therapeutics (NASDAQ:PSTI) is selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority.
  • CRISPR-IL brings together the leading experts in life science and computer science to develop artificial intelligence (AI) based end-to-end genome-editing solutions.
  • These next-generation, genome editing products for human, plant, and animal DNA, have applications in the pharma, agriculture, and aquaculture industries.
  • CRISPR is a genome-editing technology for detecting and modifying DNA sequences and is used as a tool to enable genetic changes.
  • Shares are up 2% premarket.

Recommended For You

About PLUR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PLUR--
Pluri Inc.